Theriva Biologics, Inc. 8-K

What Happened

• On June 5, 2026 Theriva Biologics, Inc. announced it called its Special Meeting of Stockholders but could not convene because not enough shares were present or represented by proxy to form a quorum.
• The Special Meeting was intended to seek stockholder approval of a warrant exercise proposal (and an adjournment proposal) described in the definitive proxy statement filed with the SEC on April 30, 2026.
• Under a warrant inducement agreement dated October 16, 2025 with certain institutional investors, the Company agreed to seek shareholder approval to allow issuance of up to 16,184,560 shares upon exercise of certain warrants; because the meeting failed to convene, the Company must call additional meetings every 60 days until approval is obtained or the warrants are no longer outstanding (unless waived by the investors).

Key Details

• Date meeting called: June 5, 2026; definitive proxy filed April 30, 2026.
• Inducement Agreement date: October 16, 2025.
• Potential shares subject to warrants: up to 16,184,560 common shares.
• Company will file and mail updated proxy materials with the date/time of the rescheduled meeting as required.

Why It Matters

• This filing alerts investors that approval to issue up to 16.18 million shares via warrant exercise remains outstanding — approval would enable warrant holders to convert into common stock, which could dilute existing shareholders.
• The Company is contractually required to keep calling meetings every 60 days until stockholder approval is obtained or the warrants lapse, creating recurring corporate actions and proxy costs until resolved.
• Investors should watch for the new meeting date and proxy materials to understand the proposals and potential dilution effects.